Core Viewpoint - The company has demonstrated resilience in a challenging industry environment by focusing on core business development and accelerating digital transformation, leading to positive financial results and growth signals in early 2025 [1][2][3] Group 1: Financial Performance - In 2024, the company achieved an outpatient volume of 16.94 million visits, a year-on-year increase of 12.14% [1] - The total number of surgeries performed reached 1.29 million, reflecting a year-on-year growth of 9.38% [1] - The company reported a revenue of 20.98 billion yuan, up 3.02% year-on-year, and a net profit attributable to shareholders of 3.56 billion yuan, which is a 5.87% increase [1] - In Q1 2025, the company indicated a revenue growth of 15.97% and a net profit increase of 16.71% year-on-year [1] Group 2: Strategic Expansion - The company continues to implement its "1+8+N" strategy, establishing the Changsha Medical Center and launching six major ophthalmology centers across various cities [2] - The company has expanded its network to 352 hospitals and 229 outpatient departments within China [2] - The establishment of nearly 100 specialized injection centers for eye diseases and management clinics for diabetic eye disease in county-level hospitals has enhanced grassroots eye care coverage [2] Group 3: Internationalization and Collaboration - The company hosted significant international ophthalmology events, including the 19th World Myopia Conference, attracting over 500 experts from more than 50 countries [2] - The acquisition of 100% of the UK-based Optimax Group marks the company's entry into the UK ophthalmology market, increasing its overseas institutions to 163 [2] Group 4: Technological Innovation - The company is advancing its "AI + Ophthalmology" initiatives, launching the AierGPT model to enhance eye health education, diagnosis, training, and management [3] - The introduction of the world's first smart glasses for children's vision management, "Little Qingkui," utilizes advanced biosensing technology and big data analytics [3] - The company has implemented a digital infection control system and achieved significant progress in data-driven quality management across its hospitals [3]

一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301103 证券简称：何氏眼科 公告编号：2025-006 辽宁何氏眼科医院集团股份有限公司2024年年度报告摘要 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 所有董事均已出席了审议本报告的董事会会议。 容诚会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所由变更为容诚会计师事务所（特殊普通合 伙）。 非标准审计意见提示 1、公司主营业务及产品 公司坚持科技创新，为客户提供个性化、智慧化的眼健康管理服务。针对用户当前的眼健康需求，公司 依托先进医疗技术、人才、诊疗设备，为各类眼病患者提供眼科全科诊疗服务，诊疗服务中除了诊治常 公司经本次董事会审议通过的利润分配预案为：以155,303,752股为基数，向全体股东每10股派发现 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 二、通过深交所交易系统投票的程序 1. 投票的时间：2025年5月22日的交易时间，即上午9:15－9:25，9:30－11:30和13:00-15:00 2. 股东可以登录证券公司交易客户端通过交易系统投票。 三、通过深交所互联网投票系统的投票程序 1. 投票时间：2025年5月22日9:15-15:00 2. 股东通过互联网投票系统进行网络投票，需按照《深圳证券交易所投资者网络服务身份认证业务指 引》的规定办理身份认证，取得"深交所数字证书"或"深交所投资者服务密码"。具体身份认证流程可登 录互联网投票系统http://wltp.cninfo.com.cn规则指引栏目查阅。 3. 股东根据获取的服务密码或数字证书，可登录http://wltp.cninfo.com.cn在规定时间内通过深交所互联 网投票系统进行投票。 附件2 辽宁何氏眼科医院集团股份有限公司 2024年年度股东大会授权委托书 辽宁何氏眼科医院集团股份有限公司： 兹委托 先生/女士代表本人/本公司出席辽宁何氏眼科医院集团股份有限公司2024年年度股东大会并代为 行使表决权。授权期限自委托书签 ...

Core Insights - Aier Eye Hospital focuses on core business and strengthens discipline construction, achieving steady growth in operating performance, outpatient visits, and surgical volume [1][2] Financial Performance - In 2024, the company reported operating revenue of 20.983 billion yuan, a year-on-year increase of 3.02% - The net profit attributable to the parent company was 3.556 billion yuan, up 5.87% - The company plans to distribute a cash dividend of 1.6 yuan per 10 shares, totaling approximately 1.487 billion yuan [1][12] Operational Growth - Outpatient visits reached 16.9407 million, a 12.14% increase year-on-year - Surgical volume was 1.2947 million cases, reflecting a 9.38% growth [2] Strategic Development - The "1+8+N" strategic layout has made significant progress, with multiple regional eye centers established [3][4] - By the end of 2024, the company operated 352 hospitals and 229 outpatient departments, highlighting its chain scale advantage [5] Quality Improvement - The company has enhanced medical quality and service levels, implementing comprehensive quality improvement actions and risk management [6] - Patient satisfaction rates are high, with an overall satisfaction rate of nearly 99.0% from over 1.6 million surveys conducted [7] Digital Transformation - Aier Eye Hospital has made significant advancements in digital ophthalmology and AI applications, establishing a competitive edge [8] - The company launched the AierGPT model and the digital human "Eyecho" in 2024 [9][10] Research and Development - The company is expanding its specialty areas, including ocular tumors and neuro-ophthalmology, while enhancing its research capabilities [11] - A total of 73 research projects were approved in 2024, with 5 at the national level, and 161 papers published, including 103 in SCI/Medline journals [11] Shareholder Returns - The company has consistently prioritized shareholder returns, with a cumulative dividend payout of 7.12 billion yuan since its listing [12][13] - Aier Eye Hospital has also implemented share buyback programs to stabilize stock prices and boost investor confidence [13] Social Responsibility - The company actively engages in social responsibility initiatives, including eye health poverty alleviation and community outreach programs [14] - In 2024, Aier Eye Hospital donated 217 million yuan to various public welfare projects, supporting 873 initiatives nationwide [14]

Core Insights - Aier Eye Hospital has demonstrated steady financial performance despite a slowing consumer market and intense competition, achieving a revenue of 20.983 billion yuan and a net profit of 3.556 billion yuan in 2024, with year-on-year growth of 3.02% and 5.87% respectively [1] - The company has initiated a new round of transformation and innovation to regain rapid growth, focusing on digitalization, model innovation, and organizational change [2] Financial Performance - In 2024, Aier Eye Hospital reported a revenue of 20.983 billion yuan and a net profit of 3.556 billion yuan, with outpatient visits reaching 16.9407 million, marking a 12.14% increase [1] - In Q1 2025, the company achieved a revenue of 6.026 billion yuan and a net profit of 1.05 billion yuan, reflecting a year-on-year growth of 15.97% and 16.71% respectively [1] Strategic Initiatives - The "1+8+N" strategic layout has begun to show results, with multiple eye centers operational across major cities in China, and ongoing projects in Beijing and Shenzhen [3] - Aier Eye Hospital has acquired 100% of the UK-based Optimax Group, expanding its international presence with 163 overseas eye centers and clinics [3] Organizational Changes - The company has established an organizational change team to enhance management efficiency, focusing on integrated management and collaborative systems [4] Medical Advancements - Aier Eye Hospital continues to introduce leading diagnostic and treatment technologies, achieving several "firsts" in the country, including the first implantation of advanced artificial lenses [5][6] - The company is committed to enhancing clinical capabilities and expanding its medical specialties, including ocular oncology and pediatric eye care [6] Digital Transformation - Aier Eye Hospital is advancing its digital transformation with projects like the development of a personalized digital human for ophthalmology, enhancing patient interaction and care [7][8] - The establishment of "AI Eye Hospital" aims to leverage AI for health education, diagnosis, and remote medical services, expanding access to care [8]

爱尔眼科：第一季度净利润同比增长16.71% 智通财经4月24日电，爱尔眼科(300015.SZ)公告称，2025年第一季度公司营业收入为60.26亿元，同比增 长15.97%；归属于上市公司股东的净利润为10.49亿元，同比增长16.71%。基本每股收益为0.1136元。 ...

爱尔眼科（300015）公告，2024年营业收入为209.83亿元，同比增长3.02%；归属于上市公司股东的净 利润为35.56亿元，同比增长5.87%；基本每股收益为0.3847元/股，同比增长5.57%；拟向全体股东每10 股派发现金红利1.6元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。 ...

前十大流通股东累计持有： 4457.22万股，累计占流通股比： 53.66%，较上期变化： -82.55万股。 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况 | | --- | --- | --- | --- | | | | (%) | (万股) | | 先进制造产业投资基金(有限合伙) | 1065.17 | 12.82 | 不变 | | 大连东软控股有限公司 | 783.14 | 9.43 | 不变 | | 沈阳新松机器人自动化股份有限公司 | 783.14 | 9.43 | 不变 | | 北京信中利美信股权投资中心(有限合伙) | 521.84 | 6.28 | -55.52 | | 中国工商银行股份有限公司-融通健康产业灵活配置混合 型证券投资基金 | 460.00 | 5.54 | -5.79 | | 共青城鹏信投资管理合伙企业(有限合伙) | 267.39 | 3.22 | -9.22 | | 黄友平 | 254.44 | 3.06 | 6.05 | | 中央企业乡村产业投资基金股份有限公司 | 137.65 | 1.66 | 不变 | | 深圳华大基因（300676）股份有限公 ...

Core Viewpoint - He Eye Hospital has decided to terminate the cross-border e-commerce project of Hainan He Eye Color Trading Co., Ltd. due to unsatisfactory performance and market conditions, aiming to enhance the efficiency of fund utilization and protect shareholder interests [1] Group 1 - The project had a total budgeted investment of 26 million yuan [1] - The decision was made during the third board and supervisory board meetings held on April 23, 2025 [1] - Remaining raised funds will be transferred to a special account for excess raised funds and the corresponding special account will be canceled [1]

Core Viewpoint - Guangzheng Eye Hospital Group Co., Ltd. reported a significant decline in revenue and net profit for 2024, indicating ongoing challenges in its business transformation efforts [2][4]. Financial Performance - The company achieved a revenue of 893 million yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders turned from profit to a loss of 175 million yuan, a drastic decline of 1987.12% year-on-year [2]. - The non-recurring net profit has remained negative for 12 consecutive years [2]. Business Segment Analysis - The medical sector generated 778 million yuan in revenue, down 6.88% year-on-year, accounting for 87.17% of total revenue [3]. - The steel structure segment saw a revenue drop of 61.78% to 79.19 million yuan, representing 8.87% of total revenue [3]. - The energy sector reported a revenue increase of 10.66% to 35.36 million yuan, making up 3.96% of total revenue [3]. Major Projects and Challenges - The refractive and cataract projects in the eye care business generated revenues of 258 million yuan and 288 million yuan, respectively, both showing declines of 13.09% and 8.88% year-on-year [3]. - The company has opened 14 specialized eye hospitals and 3 vision clinics in 10 major cities [3]. - The company has cumulatively recognized goodwill impairment provisions of 374 million yuan, with 135 million yuan recognized in 2024 alone for two acquired eye hospitals [4]. Strategic Transformation - Guangzheng Eye Hospital has undergone several strategic shifts, moving from steel structure operations to focusing on eye care services [5][6]. - The company had high expectations for its eye care business, but it has not yet yielded the anticipated results, leading to further losses [4][7]. - The competitive landscape in the eye care industry has intensified, impacting the company's revenue and profit margins [4][7].